Role of Long Non-coding RNA in Drug Resistance in Non-small Cell Lung Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2018 May 5

PMID 29726094

Citations 40

Authors

Leirong Wang

Leina Ma

Fei Xu

Wenxin Zhai

Shenghua Dong

Ling Yin

Jia Liu

Zhuang Yu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-associated death, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Many drugs have been used to treat NSCLC in order to improve patient prognosis. Platinum-based chemotherapy is the first-line treatment for locally advanced or metastatic patients. For patients with activating EGFR mutations, tyrosine kinase inhibitors are the best treatment choice. NSCLC initially exhibits an excellent response to treatment; however, acquired resistance has been observed in many patients, leading to ineffective treatment. Clinical resistance is an impediment in the treatment of patients with advanced NSCLC. Many sequencing technologies have shown that long non-coding RNA (lncRNA) is expressed differently between drug-resistant and drug-sensitive lung cancer cells. We review the literature on lncRNA in drug resistance of NSCLC. The aim of this review is to gain insight into the molecular mechanisms of drug resistance, mainly focusing on the role of lncRNA in NSCLC.

Citing Articles

A Novel Competing Endogenous RNA Network Reveals Potential Mechanisms and Biomarkers of Chemoresistance in Lung Adenocarcinoma.

Liu W, Zhou H, Qi Y, Wang P, Ning S, Huang Y J Cancer. 2025; 16(3):720-734.

PMID: 39781361 PMC: 11705065. DOI: 10.7150/jca.102148.

PTCSC3, XIST, GAS5, UCA1, and HIFAL: Five lncRNAs Emerging as Potential Prognostic Players in Egyptian Adult Acute Myeloid Leukemia (AML) Patients.

El Leithy A, Bakr Y, Hassan N, Dardeer K, Assem M, Abdel Wahab A Cancer Control. 2024; 31:10732748241309044.

PMID: 39673539 PMC: 11646343. DOI: 10.1177/10732748241309044.

Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer.

Geng R, Ren M, Ma Y, Su W Cell Biochem Biophys. 2024; .

PMID: 39499390 DOI: 10.1007/s12013-024-01592-3.

SETD1A-mediated Methylation of H3K4me3 Inhibits Ferroptosis in Non-small Cell Lung Cancer by Regulating the WTAPP1/WTAP Axis.

Wang D, Zu Y, Sun W, Fan X Curr Med Chem. 2023; 31(21):3217-3231.

PMID: 37231753 DOI: 10.2174/0929867330666230525143252.

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

Wang M, Zhu L, Yang X, Li J, Liu Y, Tang Y Front Pharmacol. 2023; 14:1132158.

PMID: 36874015 PMC: 9974851. DOI: 10.3389/fphar.2023.1132158.

References

Shi H, Pu J, Zhou X, Ning Y, Bai C . Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Tumour Biol. 2017; 39(5):1010428317697568. DOI: 10.1177/1010428317697568. View

BENTZEN , Overgaard . Patient-to-Patient Variability in the Expression of Radiation-Induced Normal Tissue Injury. Semin Radiat Oncol. 1994; 4(2):68-80. DOI: 10.1053/SRAO00400068. View

Uramoto H, Mitsudomi T . Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. Br J Cancer. 2007; 96(6):857-63. PMC: 2360106. DOI: 10.1038/sj.bjc.6603665. View

Wang B, Jiang H, Wang L, Chen X, Wu K, Zhang S . Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett. 2017; 13(5):3494-3500. PMC: 5431660. DOI: 10.3892/ol.2017.5878. View

Patel A, Simone 2nd C, Jabbour S . Risk factors and management of oligometastatic non-small cell lung cancer. Ther Adv Respir Dis. 2016; 10(4):338-48. PMC: 5933679. DOI: 10.1177/1753465816642636. View

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Ramalingam S, Owonikoko T, Khuri F . Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61(2):91-112. DOI: 10.3322/caac.20102. View

Zhang Z, Fu S, Xu S, Zhou X, Liu X, Xu Y . By downregulating Ku80, hsa-miR-526b suppresses non-small cell lung cancer. Oncotarget. 2015; 6(3):1462-77. PMC: 4359307. DOI: 10.18632/oncotarget.2808. View

Cobo M, Isla D, Massuti B, Montes A, Miguel Sanchez J, Provencio M . Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007; 25(19):2747-54. DOI: 10.1200/JCO.2006.09.7915. View

10.

Yu X, Li Z . Long non-coding RNA HOTAIR: A novel oncogene (Review). Mol Med Rep. 2015; 12(4):5611-8. DOI: 10.3892/mmr.2015.4161. View

11.

Qiao M, Sheng S, Pardee A . Metastasis and AKT activation. Cell Cycle. 2008; 7(19):2991-6. DOI: 10.4161/cc.7.19.6784. View

12.

Qian B, Wang X, Mao C, Jiang Y, Shi Y, Chen L . Long non-coding RNA linc01433 promotes migration and invasion in non-small cell lung cancer. Thorac Cancer. 2018; 9(5):589-597. PMC: 5928388. DOI: 10.1111/1759-7714.12623. View

13.

Zhang H, Pang M, Dong W, Xin J, Li Y, Zhang Z . miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 2014; 31(3):1473-9. DOI: 10.3892/or.2014.2973. View

14.

Witta S, Gemmill R, Hirsch F, Coldren C, Hedman K, Ravdel L . Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66(2):944-50. DOI: 10.1158/0008-5472.CAN-05-1988. View

15.

Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F . Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012; 8(9):2289-94. DOI: 10.1039/c2mb25070e. View

16.

Ouyang S, Zheng X, Zhou X, Chen Z, Yang X, Xie M . LncRNA BCAR4 promotes colon cancer progression via activating Wnt/β-catenin signaling. Oncotarget. 2017; 8(54):92815-92826. PMC: 5696224. DOI: 10.18632/oncotarget.21590. View

17.

Wang L, Hu Y, Xiang X, Qu K, Teng Y . Identification of long non-coding RNA signature for paclitaxel-resistant patients with advanced ovarian cancer. Oncotarget. 2017; 8(38):64191-64202. PMC: 5609994. DOI: 10.18632/oncotarget.19828. View

18.

Orom U, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G . Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010; 143(1):46-58. PMC: 4108080. DOI: 10.1016/j.cell.2010.09.001. View

19.

Chirnomas D, Taniguchi T, de la Vega M, Vaidya A, Vasserman M, Hartman A . Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006; 5(4):952-61. DOI: 10.1158/1535-7163.MCT-05-0493. View

20.

Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T . Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 2005; 51(1):71-7. DOI: 10.1016/j.lungcan.2005.08.006. View